Drug Pricing Reform Gathers Steam (Part 2)
FDA Law Blog
SEPTEMBER 14, 2021
PART 1: MAXIMUM FAIR PRICE PAYMENT LIMITATION UNDER MEDICARE PARTS B AND D AND THE COMMERCIAL INSURANCE MARKET. The MFP would be established through negotiations between HHS and the manufacturer and would incorporate foreign pricing benchmarks, as further described below. The four parts of Subtitle E are summarized in turn below.
52 
Let's personalize your content